Form 4: Lantern Pharma CFO Granted 20,000 Stock Options

Lantern Pharma Inc.'s Chief Financial Officer, David R. Margrave, was granted 20,000 stock options with an exercise price of $3.24 per share.

Summary

• David R. Margrave, Chief Financial Officer of Lantern Pharma Inc. (LTRN), acquired 20,000 stock options.
• The options have an exercise price of $3.24 per share.
• These options were granted on December 18, 2025, under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
• The options will vest in equal monthly increments over a 24-month period, commencing January 18, 2026.
• The options are exercisable from January 18, 2026, and expire on December 17, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management alignment and long-term incentive. The specific exercise price and vesting schedule are standard, reflecting a commitment to future performance.

Positives

• The grant of stock options to a key executive like the CFO aligns management's interests with shareholder value, incentivizing long-term performance.
• The options are granted under an existing, approved stock incentive plan, indicating a structured approach to executive compensation.

Negatives

• The exercise price of $3.24 sets a benchmark; if the stock price does not rise above this, the options may not be in-the-money, potentially limiting their incentive effect.

Future Outlook

The vesting schedule over 24 months, commencing January 18, 2026, indicates a long-term incentive structure designed to retain and motivate the Chief Financial Officer, aligning their future performance with the company's stock appreciation.

Industry Context

The granting of stock options is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, particularly in companies like Lantern Pharma that are often in development stages and rely on long-term value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of management interests with shareholder value creation, as the CFO is incentivized by stock price appreciation.
• Employees: May signal a stable executive team and a commitment to performance-based compensation.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a key executive, the CFO. While it aligns management incentives with shareholder interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Lantern Pharma, LTRN, Stock Option, CFO, David R. Margrave, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Stock Incentive Plan